Immunic
IMUX
59 hedge funds and large institutions have $75.7M invested in Immunic in 2024 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 19 increasing their positions, 7 reducing their positions, and 10 closing their positions.
234% more capital invested
Capital invested by funds: $22.7M → $75.7M (+$53M)
171% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 7
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
20% more funds holding
Funds holding: 49 → 59 (+10)
3.02% more ownership
Funds ownership: 3.35% → 6.38% (+3%)
84% less call options, than puts
Call options by funds: $67K | Put options by funds: $418K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$11.6M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$11.6M |
| 3 |
Janus Henderson Group
London,
|
+$9.09M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$9.09M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$562K |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$493K |
| 3 |
SSA
Sierra Summit Advisors
Incline Village,
Nevada
|
-$487K |
| 4 |
CAC
Cowen and Company
New York
|
-$476K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$415K |
IMUX Hedge Fund Activity: Q1 2024 in Review
59 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q1 2024, worth a combined $75.7M — up 234% from $22.7M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new IMUX positions and 10 closed out — a net gain of 10 holders — while 19 added to existing stakes and 7 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $11.6M. The largest seller was UBS O'Connor, cutting an estimated $562K.
- 59 institutional investors held Immunic (IMUX) as of Q1 2024, up from 49 in Q4 2023.
- Funds reported $75.7M of Immunic stock for Q1 2024, up 234% quarter-over-quarter.
- 20 funds opened new Immunic positions in Q1 2024 and 10 closed out, a net change of +10 holders.
- The largest Immunic buyer in Q1 2024 was Avidity Partners Management, an estimated $11.6M added.
- The largest Immunic seller in Q1 2024 was UBS O'Connor, an estimated $562K sold.
Based on aggregated 13F filings for Q1 2024.